Atopic dermatitis (AD) is typically a big issue during early childhood. But it also afflicts up to 5% of adults. Mild cases, which are virtually always managed in primary care, are usually ...

The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and efficacy of the drug, which ...

Please provide your email address to receive an email when new articles are posted on . Patients with drug reactions with eosinophilia and systemic symptoms show increases in Th2-associated cytokines.

Please provide your email address to receive an email when new articles are posted on . Incidence rates for cancers included 12.88 for the exposed group and 15.04 for the unexposed group. Adjusting ...

The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents. The association between dupilumab and psoriasis was ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

Eosinophilic esophagitis is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, proliferate in the esophagus, causing difficulties with eating and swallowing. The FDA ...

Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab. Dupilumab was associated with higher ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...

An anti-inflammation injectable drug can reduce mucus buildup and improve breathing among asthma patients, a new clinical trial says. The drug dupilumab (Dupixent) effectively clears up airways ...